Summary:
We evaluated 40 patients undergoing high-dose chemo/radiotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT) (allogeneic (22), autologous (18)) to determine the safety and feasibility of administering low molecular weight heparin (LMWH) as hepatic veno-occlusive disease (VOD) prophylaxis. Patients received a once daily subcutaneous injection of dalteparin 2500 anti-Xa i.u. commencing the day prior to starting HDCT, and continuing until day +30 post HSCT or hospital discharge, whichever came first. Dosage adjustments were made for patients developing renal failure. All bleeding episodes were recorded and graded and VOD was diagnosed and graded according to Seattle criteria. At 100 days of follow-up, the overall survival and probability of regimen-related mortality were 85 and 15%, respectively. Nine patients developed VOD. The probability of developing VOD post allogeneic and autologous HSCT was 28% (95% CI, 6–45) and 17% (95% CI, 0–32), respectively. VOD was graded as moderate (n=8) and severe (n=1). VOD resolved in all cases except for one patient who died secondary to severe VOD and multiorgan failure. Clinically significant bleeding episodes occurred in three patients; 24 patients developed minor bleeding not requiring specific therapy. All bleeding episodes resolved. These results suggest that LMWH for VOD prophylaxis is safe with a low incidence of serious bleeding events. Whether it is superior to unfractionated heparin, however, is unknown and should be addressed within the context of a randomized controlled trial.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562.
McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 16.
Jones RJ, Lee KSK, Beschorner WE et al. Venocclusive disease of the liver following bone marrow transplantation. Transplant 1987; 44: 778.
Dulley FL, Kanfer EJ, Appelbaum FR et al. Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplant 1987; 43: 870.
Ayash LJ, Hunt M, Antman K et al. Hepatic venocclusive disease in autologous bone marrow transplantation of solid tumors and lymphomas. J Clin Oncol 1990; 8: 1699.
McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255.
Bearman SI . The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005.
Richardson P, Guinan E . The pathology, diagnosis, and treatment of hepatic veno-occlusive disease: current status and novel approaches. Br J Haematol 1999; 107: 485.
Shulman HM, Fisher LB, Schoch HG et al. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 1171.
Shulman HM, Hinterberger W . Hepatic veno-occlusive disease—liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197.
Rozman C, Carreras E, Qian C et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75.
Kami M, Mori S, Tanikawa S et al. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution. Bone Marrow Transplant 1997; 20: 397.
Carreras E, Bertz H, Arcese W et al. On behalf of the European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European group for blood and marrow transplantation. Blood 1998; 92: 3599.
Gluckman E, Jolivet I, Scrobohaci ML et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74: 277.
Attal M, Huguet F, Rubie H et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. Blood 1993; 82: 732.
Clift RA, Bianco JA, Appelbaum FR et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 892: 2025.
Essell JH, Schroeder MT, Harman GS et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975.
Ruutu T, Eriksson B, Remes K et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977.
Rio BY, Lamy T, Zittoun R . Preventive role of heparin for liver veno-occlusive disease (VOD). Bone Marrow Transplant 1988; 3: 266.
Bearman SI, Hinds MS, Wolford JL et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407.
Marsa-Vila L, Gorin NC, Laporte JP et al. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47: 346.
Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective randomized trial. Blood 1992; 79: 2834.
Cahn JY, Flesch M, Brion A et al. Prevention of veno-occlusive disease of the liver after bone marrow transplantation: heparin or no heparin? Blood 1992; 80: 2149.
Hirsh J, Levine MN . Low molecular weight heparin. Blood 1992; 79: 1.
Bergqvist D, Matzsch T, Burmark US et al. Low molecular weight heparin given the evening before surgery compared with conventional low dose heparin in prevention of thrombosis. Br J Surg 1988; 75: 888.
Caen JP . A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep vein thrombosis in general surgery. Thromb Haemost 1988; 59: 216.
Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682.
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
Richardson PG, Murakami C, Jin Z et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337.
Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330.
Or R, Nagler A, Shpilberg O et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplant 1996; 61: 1067.
Nevo S, Enger C, Hartley E et al. Acute bleeding and thrombocytopenia after bone marrow transplantation. Bone Marrow Transplant 2001; 27: 65.
Acknowledgements
We acknowledge the contribution of the medical and nursing staff of 8A/B Ward and Medical Day Unit at the QEII Health Sciences Centre.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Forrest, D., Thompson, K., Dorcas, V. et al. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 31, 1143–1149 (2003). https://doi.org/10.1038/sj.bmt.1704087
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704087
Keywords
This article is cited by
-
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant
Bone Marrow Transplantation (2022)
-
Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD)
Bone Marrow Transplantation (2019)
-
Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy
Bone Marrow Transplantation (2017)
-
Experiences of t-PA use in moderate-to-severe hepatic veno-occlusive disease after hematopoietic SCT: is it still reasonable to use t-PA?
Bone Marrow Transplantation (2013)
-
Hepatic Toxicity After Radioembolization of the Liver Using 90Y-Microspheres: Sequential Lobar Versus Whole Liver Approach
CardioVascular and Interventional Radiology (2012)